Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
NCT05732831 · View on ClinicalTrials.gov ↗
Study Summary
This is a first in human study in patients with advanced or metastatic solid tumors known to have an MTAP deletion. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific MTAP-deleted tumor types. The study drug, TNG462, is a selective PRMT5 inhibitor administered orally. The study is planned to treat up to 225 participants.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG TNG462
Study Locations (20)
Other
- CHU de Brest — Brest
- Centre Berard Leon — Lyon
- Institut de Cancerologie de l'Ouest - Hôpital Saint Herblain - PPDS — Saint-Herblain
- Institute Gustav Roussy — Villejuif
Illinois
- University Chicago Medicine — Chicago
- Carle Cancer Center — Urbana
- Midwestern Regional Medical Center, City of Hope Chicago — Zion
Florida
- Florida Cancer Specialists & Research Institute — Lake Mary
- Sylvester Comprehensive Cancer Center — Miami
Massachusetts
- Massachusetts General Hospital — Boston
- Dana Farber Cancer Institute — Boston
California
- Stanford University — Palo Alto
Colorado
- Grand Valley Oncology — Grand Junction
Michigan
- Henry Ford Cancer Center — Detroit
New York
- New York University Langone Health — New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 225 participants |
| Start Date | 2023-05-26 |
| Est. Completion | 2026-09 |
| Phase | Phase 1 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05732831
The ClinicalTrials.gov registry entry for NCT05732831 describes a study currently listed as recruiting. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 225 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tango Therapeutics, which has 36 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Locally Advanced Solid Tumor appearing as the primary indexed condition, and to 2 interventions — of which Pembrolizumab is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT05732831 reports 20 study locations spanning 13 distinct geographic areas — top geographies include Other, Illinois, Florida. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT05732831 about?
NCT05732831 is a clinical study titled "Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors". This is a first in human study in patients with advanced or metastatic solid tumors known to have an MTAP deletion. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific MTAP-deleted tumor types. The study drug, TNG462, is a sel...
What is the current status of trial NCT05732831?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 225 participants. The study started on 2023-05-26. Estimated completion is 2026-09.
What conditions does trial NCT05732831 study?
This clinical trial studies the following conditions: Locally Advanced Solid Tumor. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT05732831?
The interventions under investigation include: Pembrolizumab (DRUG), TNG462 (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT05732831?
This trial is sponsored by Tango Therapeutics, which has 36 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT05732831 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.